These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2010480)

  • 1. Recombinant erythropoietin and chronic renal failure.
    Lundin AP
    Hosp Pract (Off Ed); 1991 Apr; 26(4):61-9. PubMed ID: 2010480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects.
    Nissenson AR; Nimer SD; Wolcott DL
    Ann Intern Med; 1991 Mar; 114(5):402-16. PubMed ID: 1992884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin treatment for anemia in end-stage renal disease with diabetes mellitus.
    Nakatsuka K; Hino M; Miki T; Nishizawa Y; Tabata T; Inoue T; Morii H
    Diabetes Care; 1990 Nov; 13(11):1130-1. PubMed ID: 2261828
    [No Abstract]   [Full Text] [Related]  

  • 6. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 7. Erythropoietin.
    Haberl M
    Aust Nurses J; 1990 Sep; 20(2):29. PubMed ID: 2268202
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
    Nissenson AR
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):25-31. PubMed ID: 2669083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythropoietin: the developing story.
    Cotes PM
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):805-6. PubMed ID: 3130919
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of withdrawing erythropoietin.
    Taylor JE; Henderson IS; Mactier RA; Stewart WK
    BMJ; 1991 Feb; 302(6771):272-3. PubMed ID: 1998794
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 14. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
    Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M
    Contrib Nephrol; 1990; 82():49-54. PubMed ID: 2093526
    [No Abstract]   [Full Text] [Related]  

  • 15. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant human erythropoietin: factors to consider in cost-benefit analysis.
    Sheingold SH; Churchill DN; Muirhead N; Laupacis A
    Am J Kidney Dis; 1991 Jan; 17(1):86-92. PubMed ID: 1898836
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial.
    Kleinman KS; Schweitzer SU; Perdue ST; Bleifer KH; Abels RI
    Am J Kidney Dis; 1989 Dec; 14(6):486-95. PubMed ID: 2688405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. rHuEpo before dialysis and in dialysed patients.
    López-Gómez JM; Jofre R; Moreno F; Verde E; Valderràbano F
    Nephrol Dial Transplant; 1995; 10 Suppl 6():31-5. PubMed ID: 8524491
    [No Abstract]   [Full Text] [Related]  

  • 19. Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'?
    Vlassopoulos D; Sonikian M; Dardioti V; Hadjiconstantinou V
    Nephrol Dial Transplant; 1999 May; 14(5):1340-1. PubMed ID: 10344405
    [No Abstract]   [Full Text] [Related]  

  • 20. [Initial response to treatment with erythropoietin in anemia caused by chronic renal insufficiency].
    Sánchez Casajús A; Barrau J; Gómez Alamillo C; Jaurrieta F
    Sangre (Barc); 1990 Feb; 35(1):82-4. PubMed ID: 2333585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.